Lupin Ltd (LUPIN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Lupin Ltd on NSE and BSE, with an AI summary of each filing.
Investor Presentation- Q2 FY2027
Investor Presentation · 04 Nov 2026, 7:22 am
Lupin Q2 FY27 Results: 14% Sales Growth Amid Margin Contraction Lupin reported net sales of INR 77,855 mn for Q2 FY27, up 14.0% YoY but down 5.3% QoQ. EBITDA declined 8.4% YoY to INR 19,574 mn, with EBITDA margin contracting to 25.1% from 31.3% in Q2 FY26. Net income fell 21.8% YoY to INR 11,553 mn. India sales grew 15% YoY to INR 23,836 mn, while US sales rose 10% YoY to INR 31,696 mn ($317 mn, down 13% QoQ). The balance sheet remained net cash with net debt-to-equity at (0.14).
Lupin Q2 FY2027 Results
Press Release · 04 Nov 2026, 7:18 am
Lupin Q2 FY27 Results: Sales Grow 14% While Profitability Contracts Lupin reported consolidated sales of INR 77,855 Mn for Q2 FY27, up 14.0% YoY but down 5.3% QoQ. EBITDA declined 10.7% YoY to INR 21,712 Mn, with margins contracting 770 bps YoY to 27.9%, pressured by higher personnel and manufacturing costs. PAT dropped 22.2% YoY to INR 11,553 Mn. Geographically, U.S. sales rose 9.3% YoY to INR 30,202 Mn, India grew 14.7% to INR 23,836 Mn, and Other Developed Markets surged 45.7%. R&D investments reached INR 6,181 Mn (7.9% of sales). As of 30th Sep'26, net debt stood at INR -33,490 Mn.
Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with ....
Change in Management · 04 Nov 2026, 6:44 am
Lupin Appoints Akhil Gupta as Independent Director for Five-Year Term Lupin Limited's Board of Directors approved the appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective 3rd Nov'26, and as an Independent Director for a five-year term running from 3rd Nov'26 to 2nd Nov'31, subject to shareholder approval. Mr. Gupta, a Chartered Accountant and former Vice Chairman of Bharti Enterprises with over four decades of experience, currently chairs 360 ONE WAM and Coforge. His appointment strengthens the board with extensive expertise in corporate governance, strategy, and mergers and acquisitions.
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
Financial Result · 04 Nov 2026, 6:31 am
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
Outcome · 04 Nov 2026, 6:21 am
Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Outcome · 04 Nov 2026, 6:14 am
Lupin Reports Q2 FY27 Consolidated Financial Results Lupin reported consolidated revenue from operations of ₹78,272.6 million for the quarter ended 30th Sep'26, up 11.06% YoY from ₹70,475.1 million, but down 5.43% QoQ. Consolidated net profit after tax declined 22.19% YoY and 18.47% QoQ to ₹11,553.0 million, resulting in a diluted EPS of ₹25.14. For H1 ended 30th Sep'26, consolidated revenue grew 20.94% YoY to ₹161,041.5 million, while net profit contracted 4.95% YoY to ₹25,722.8 million. Standalone operations posted a net loss of ₹59.1 million for the quarter.
Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States.
Press Release · 04 Nov 2026, 1:08 am
Lupin Launches Raltegravir Tablets in US with 180-Day Generic Exclusivity Lupin Limited has launched Raltegravir Tablets USP, 600 mg in the US following US FDA approval for its ANDA. The product is bioequivalent to Merck Sharp & Dohme's reference listed drug Isentress HD Tablets, 600 mg, indicated for HIV-1 treatment. As the exclusive first-to-file applicant, Lupin is eligible for 180-day generic drug exclusivity. According to IQVIA MAT Sep'26 data, Raltegravir Tablets USP, 600 mg recorded estimated annual US sales of USD 26 million.
Lupin Receives U.S. FDA Approval for Amifampridine Tablets.
Press Release · 02 Nov 2026, 11:34 pm
Lupin Secures US FDA Approval for Amifampridine Tablets with 180-Day Shared Exclusivity Lupin has received US FDA approval for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg, bioequivalent to Catalyst Pharmaceuticals' reference listed drug, Firdapse Tablets, 10 mg. As one of the first ANDA applicants, Lupin is eligible for 180 days of shared generic exclusivity in the US market.
U.S. FDA has concluded an inspection at Company''s manufacturing facility located in Goa, India.
Others (Uncategorized) · 24 Oct 2026, 8:08 pm
US FDA Concludes Inspection at Lupin’s Goa Facility with Form-483 Observation Lupin Limited announced that the US FDA concluded an inspection at its manufacturing facility in Goa, India, conducted from 19th Oct'26 to 23rd Oct'26. The inspection closed with the issuance of a Form-483 with one observation. The company stated it will address the observation and respond to the US FDA within the stipulated timeframe, reiterating its commitment to maintaining CGMP compliance across all facilities.
Intimation of allotment of 3,033 equity shares under ESOP.
Others (Uncategorized) · 23 Oct 2026, 10:04 pm
Lupin Allots 3,033 Equity Shares Under ESOP Scheme Lupin Limited's Operations and Finance Committee approved the allotment of 3,033 fully paid-up equity shares of face value ₹2 each on 23rd Oct'26, pursuant to the exercise of vested stock options by eligible employees of the company and its subsidiaries. Consequently, the company's issued and paid-up equity share capital expanded to ₹91,45,86,010, divided into 45,72,93,005 equity shares of ₹2 each.
Lupin Appoints Brian Savage as President, Chief Legal Officer.
Press Release · 23 Oct 2026, 3:29 pm
Lupin Appoints Brian Savage as President and Chief Legal Officer Lupin Limited announced the appointment of Brian Savage as President, Chief Legal Officer on 23rd Oct'26. Based in New Jersey, Savage will oversee the company's global Legal, Compliance, and Intellectual Property Management Group functions. He joins from Teva Pharmaceuticals, where he served since 2015 in senior leadership roles, most recently as Executive Vice President and Interim Global Chief Legal Officer, as well as General Counsel for U.S. Generics. The strategic hire aims to strengthen Lupin’s governance framework and global regulatory navigation.
Intimation about the Appointment of Senior Management Personnel.
Change in Management · 23 Oct 2026, 4:00 am
Lupin Appoints Brian Savage as President and Chief Legal Officer Lupin Limited has appointed Brian Savage as Senior Management Personnel, designated as President and Chief Legal Officer, effective 22nd Oct'26. In this full-time role, Savage will lead the company's global legal, compliance, and intellectual property (IP) functions. He brings extensive global pharmaceutical experience, having previously served as Executive Vice President and Interim Global Chief Legal Officer at Teva Pharmaceuticals, as well as practicing law at Dechert LLP.
Intimation regarding Grant of 40,157 Stock Options under Lupin Employees Stock Option Scheme 2025.
Others (Uncategorized) · 20 Oct 2026, 12:33 am
Lupin Grants 40,157 Stock Options Under ESOP Scheme 2025 Lupin's Nomination and Remuneration Committee approved the grant of 40,157 stock options to eligible employees of the company and its subsidiaries on 19th Oct'26 under the Lupin Employees Stock Option Scheme 2025. Each option is convertible into one equity share at an exercise price of ₹2.00 per share. Vesting occurs in three equal annual tranches of one-third starting one year post-grant, subject to performance criteria, with a maximum exercise period of eight years from the grant date.
Lupin Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 03 Nov 2026, 5:30 am
Schedule of Earnings Call for Q2 FY27
Intimation · 04 Nov 2026, 6:00 pm
Lupin Schedules Q2 FY27 Earnings Call for November 2026 Lupin Limited announced that its earnings conference call to discuss Q2 FY27 financial results is scheduled for Wednesday, 4th Nov'26, at 18:00 IST. The meeting will be hosted via Zoom, with participant registrations open ahead of the event.
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....
Intimation · 03 Nov 2026, 5:30 am
Lupin Schedules Board Meeting on 3rd Nov'26 for Q2 Financial Results Lupin Limited has scheduled its Board of Directors meeting on 3rd Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company securities has been closed since 1st Oct'26 and will reopen on 6th Nov'26, 48 hours post-result declaration.
To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.
Intimation · 03 Nov 2026, 5:30 am
ESG Rating by NSE Sustainability Ratings and Analytics Limited.
Others (Uncategorized) · 15 Oct 2026, 11:40 pm
NSE Sustainability Assigns Lupin ESG Rating of 70 for FY26 NSE Sustainability Ratings and Analytics Limited independently assigned Lupin an Environmental, Social, and Governance (ESG) rating of '70' for FY26, compared to '71' in FY25. The one-point marginal decline reflects lower scores in the Social and Governance parameters, which dropped by one point each. The company stated that it did not engage the agency for this assessment, which was conducted independently using publicly available information.
Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP
Press Release · 09 Oct 2026, 2:28 am
Lupin Secures U.S. FDA Approval for Phytonadione Injectable Emulsion Prefilled Syringe Lupin Limited received U.S. FDA approval on 8th Oct'26 for its ANDA covering Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL single-dose prefilled syringe. The generic is bioequivalent to International Medication Systems' reference listed drug and is indicated for the treatment and prophylaxis of hypoprothrombinemia and vitamin K-deficiency. According to IQVIA MAT Aug'26 data, Phytonadione Injectable Emulsion generated estimated annual sales of USD 52.3 million in the U.S. market, expanding Lupin’s injectable portfolio.
Lupin Launches Formoflo-G MDI, World''s First Fixed-dose Triple Combination Drug for COPD Management.
Press Release · 06 Oct 2026, 3:06 pm
Lupin Launches World's First Fixed-Dose Triple Combination Inhaler for COPD in India Lupin Limited launched Formoflo-G MDI on 6th Oct'26, the world’s first fixed-dose triple-combination metered-dose inhaler for chronic obstructive pulmonary disease (COPD) management, following DCGI approval. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate into a twice-daily, single-strength inhaler to treat moderate-to-severe COPD. Targeting a domestic patient pool exceeding 55 million individuals, the launch enhances Lupin’s domestic respiratory portfolio, where it holds the #2 market rank according to IQVIA MAT Mar'26 data.
Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which MPPI has become a step-down wholly owned subsidiary of the Company effective ....
Others (Uncategorized) · 01 Oct 2026, 3:39 pm
Lupin Subsidiary MPPI Completes Share Buyback, Becoming Wholly Owned Step-Down Unit Lupin Limited announced that Multicare Pharmaceuticals Philippines, Inc. (MPPI) completed the buyback of 30,559 shares. Following this transaction, effective 1st Oct'26, MPPI has become a wholly owned subsidiary of Netherlands-based Nanomi B.V. and consequently a step-down wholly owned subsidiary of Lupin Limited.
Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension.
Press Release · 28 Sept 2026, 2:41 pm
Lupin Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension Lupin has received tentative approval from the US FDA on 28th Sep'26 for its New Drug Application for Apixaban Oral Suspension (1.25 mg/mL) under the 505(b)(2) pathway. The product represents a novel oral liquid formulation of apixaban—the active ingredient in Bristol Myers Squibb's Eliquis—designed for adult anticoagulation patients facing difficulty swallowing tablets. Upon receipt of final approval, the drug will be manufactured at Lupin's Somerset facility in New Jersey, strengthening the company's differentiated product portfolio and US market presence.
Intimation of allotment of 24,111 equity shares under ESOP.
Others (Uncategorized) · 21 Sept 2026, 9:44 pm
Lupin Allots 24,111 Equity Shares Under Employee Stock Option Plans Lupin's Operations and Finance Committee allotted 24,111 fully paid-up equity shares of face value ₹2 each on 21st Sep'26, following the exercise of vested options under employee ESOP schemes. Consequently, the company's issued and paid-up share capital expanded to ₹91,45,79,944, comprising 45,72,89,972 equity shares of ₹2 each.
Intimation about participating in the Analyst/Institutional Investors Meet.
Intimation · 08 Sept 2026, 10:08 pm
Lupin to Participate in Kotak and J.P. Morgan Investor Conferences Lupin Limited announced its participation in upcoming institutional investor group meetings. The company is scheduled to attend the Kotak Healthcare Conference in person on 17th Sep'26, followed by the J.P. Morgan India Conference in person on 21st Sep'26. Any presentations made during these events will align with materials already publicly available on the company and stock exchange websites.
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.
Press Release · 04 Sept 2026, 11:12 pm
Lupin Secures U.S. FDA Approval for Generic Modafinil Tablets Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP (100 mg and 200 mg) on 4th Sep'26. The product is a generic equivalent of Nuvo Pharmaceuticals' Provigil Tablets, indicated to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea, or shift work disorder. According to IQVIA MAT Jul'26 data, Modafinil Tablets had estimated annual sales of USD 70.7 million in the U.S. market.